AC Immune SA reports results for the quarter ended June 30 - Earnings Summary

AC Immune AG

05/08/2026 14:27

AC Immune SA ACIU.OQ reported quarterly adjusted earnings of 2 rappen​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -21 rappen.  The mean expectation of four analysts for the quarter was for a loss of 11 rappen per share. Wall Street expected results to range from -20 rappen to 4 rappen per share.
Revenue rose 1,057.2% to CHF15.11 million from a year ago; analysts expected CHF6.74 million. 
AC Immune SA's reported EPS for the quarter was 2 rappen​.
The company reported quarterly net income of CHF1.87 million.
AC Immune SA shares had fallen by 4.6% this quarter and lost 27.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 66.1% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for AC Immune SA is $9.47, about 76% above its last closing price of $2.27
This summary was machine generated from LSEG data August 5 at 01:27 p.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.11
0.02
Beat
Mar. 31 2026 
-0.15
-0.15
Met
Dec. 31 2025 
-0.17
-0.13
Beat
Sep. 30 2025 
-0.19
-0.16
Beat